Effectiveness of SAMITAL ® for Management of Chemo/Radiotherapy-Induced Oral Mucositis in Patients with Cancer—a Systematic Review

AbstractPurpose of ReviewData from previous clinical trials indicate that SAMITAL ® significantly decreases the severity of chemo/radiotherapy-induced oral mucositis (OM) in both adult and pediatric patients undergoing treatment for a wide range of malignancies. However, there is a lack of reliable evidence-backed literature for the extensive use of SAMITAL® for the management of chemo/radiotherapy-induced OM in cancer patients. This systematic review aimed to compare the available data on the efficacy of SAMITAL® for the prevention and management of oral mucositis in patients undergoing chemo/radiotherapy.Recent FindingsTwo studies found that SAMITAL ® was effective in reducing OM in patients undergoing chemo/radiotherapy. In the other two studies, it was found that in cases where compliance was good, the incidence and severity of OM in patients undergoing chemo/radiotherapy were low.SummaryOral mucositis (OM) is one of the most common dose-limiting toxic effects of chemo/radiotherapy. Despite the predictability of OM and its negative implications on the treatment outcome of patients with cancer, an effective therapy for OM has long remained elusive. SAMITAL ® is a combination of three highly standardized botanical drug extracts fromVaccinium myrtillus [bilberry],Macleaya cordata fruits, andEchinacea angustifolia roots. Six databases: PubMed, Scopus, Cochrane, Science Direct, Lilac, and Google scholar were searched without any date filter to obtain the relevant articles...
Source: Current Oral Health Reports - Category: Dentistry Source Type: research